Est. 2001·3,000+ placements · six offices · four regions
Biogen — source image

Image via Endpoints News

Ma Activitycurated sourcedetected 2026-06-26 · confidence 95%

Last updated

Biogen: Ma Activity

Biogen acquired Apellis Pharmaceuticals for $5.6B and subsequently paused or canceled the majority of research programs that came with the acquisition, laying off a small number of employees from Apellis.

Source: Endpoints News

The leadership read

Consolidation of this kind shifts demand toward integration and transformation leadership bench strength in biotech & pharma.

Market context: Against a Talent Market Index of 107.8 (Hot) (up 2.4 month-on-month), Americas is at rising (+15.4pts) on signal share.

Biogen: 4 signals in the last 90 days — above the Biotech & Pharma median of 1 across 25 tracked companies; 0.2% of MitchelLake's Americas signal flow; 4 tracked across 51 days.

MitchelLake in this thematic

Also at Biogen

More signals across Biotech & Pharma

Ma Activity · Americas

Gilead Sciences

Gilead Sciences acquires Tubulis GmbH for $3.15B to expand oncology portfolio

Ma Activity · Americas

Bora Pharmaceuticals

Bora Group announced acquisition of MacroGenics' GMP manufacturing operations and CDMO business for US$122.5 million plus up to US$5 million contingent consideration. Includes biologics manufacturing facility in Rockville, Maryland with substantial backlog.

Product Launch · Americas

Bristol Myers Squibb

Bristol Myers Squibb announced FDA acceptance of its New Drug Application for mezigdomide, an oral CELMoD candidate for relapsed or refractory multiple myeloma combination therapy.

Capital Raising · Americas

BridgeBio

BridgeBio secured funding to support drug launch; United Airlines made an investment into the cell therapy space

Partnership · Americas

Basecamp Research

Basecamp Research integrated its EDEN antibiotic and vaccine design models into Claude Science, enabling scientists to design antibiotics and prioritize vaccine targets through Claude's interface.

Product Launch · Americas

Bota Biosciences

Bota Biosciences released Biology Protocol Language (BPL) and BPL-COGEN, a compiler-verified protocol language and generation pipeline for AI-driven biomanufacturing, announced on bioRxiv.

Weekly briefing

Track companies like Biogen — with our analysis

Anyone can set an alert for one company. We send a weekly read on the whole peer set — who's moving, and what it means for leadership. Pick what to follow:

Intelligence powered by Autonodal ↗

Nearby in the record

Share: WhatsApp · X · Email